



Universiteit  
Leiden  
The Netherlands

**Imaging in pre-clinical cancer research : applied to bone metastases**  
Snoeks, T.J.A.

**Citation**

Snoeks, T. J. A. (2012, June 13). *Imaging in pre-clinical cancer research : applied to bone metastases*. Retrieved from <https://hdl.handle.net/1887/19081>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/19081>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/19081> holds various files of this Leiden University dissertation.

**Author:** Snoeks, Thomas Jan Adriaan

**Title:** Imaging in pre-clinical cancer research : applied to bone metastases

**Date:** 2012-06-13

# 1

General Introduction


## Breast Cancer; a Perspective

Over the last decades, the prognosis of breast cancer has been much improved (Figure 1.1). For instance, the five year survival rate based on all cases registered by the United States Surveillance Epidemiology and End Results (SEER) program in 2001–2007 was 89% compared to 60% in the 1950s.<sup>1</sup> Based on the same SEER data, approximately 12% of the women born in the U.S. today will eventually develop breast cancer during their lifetime.

The chance of survival depends strongly on the stage of the disease at the moment of diagnosis. The 5 year survival rate of breast cancer patients with localized disease is 98% compared to only 23% for patients with distant metastases. This shows that a large number of patients carrying distant metastases cannot be cured. Consequently, treatment of these patients is mainly palliative, aimed at prolonging life and improving the quality of life.<sup>1,2</sup>

Autopsy revealed bone metastases in approximately 70% off all patients who died of breast cancer.<sup>3,4</sup> This preference of breast cancer to metastasize to bone, a characteristic shared with prostate cancer, has already been noted by Stephen Paget in 1889. As a metaphor describing this characteristic he wrote that “When a plant goes to seed, its seeds are carried in all directions; but they can only live and grow if they fall on congenial soil”.<sup>5</sup> This so called seed and soil hypotheses still holds true today, be it slightly rephrased to fit present day scientific knowledge.

Bone metastases are especially difficult to treat due to a strong positive feedback loop between the tumor and the bone micro-environment.<sup>6</sup> Tools to follow treatment response in a pre-clinical setting of both tumor and bone related processes such as tumor growth, angiogenesis, expression of enzymes and signaling molecules, osteolysis and bone formation are needed in research towards better treatment of bone metas-



**Figure 1.1: Five-year survival of breast cancer patients by year of diagnosis.** The five-year survival of all female breast cancer patients has been steadily increasing over the last decades. This can be explained by better treatments on one hand and earlier diagnosis due to extensive mammography screening on the other hand.<sup>1</sup>

tases. Only approaches that are capable of following all of these processes will enable a researcher to get a complete understanding in disease progression and treatment efficacy.

Molecular imaging has become one of the main tools in cancer research. The possibility to perform both structural and functional imaging make molecular imaging modalities an attractive research tool. The integrated data handling of different imaging modalities and their possible role in cancer research are discussed within this thesis. The described approaches have been applied in the evaluation of a new compound, ENMD-1198, as possible beneficial compound in the treatment of bone metastases in a pre-clinical mouse model.

## Metastatic Bone Disease


Before evaluating the use of various imaging approaches in the field of bone metastases research, it is important to have a general understanding of the biology and pathophysiology of this specific type of metastases. Both breast and prostate cancer have a strong preference to metastasize to bone. In the bone micro-environment, breast cancer is more likely to result in osteolytic lesions while prostate cancer results mainly in osteoblastic lesions, but also mixed lesions exist in some cases.<sup>7,8</sup> The complications caused by bone metastasis are vast; osteolytic lesions may result in severe bone pain, fracture, life-threatening hypercalcaemia and nerve compression, whereas, osteoblastic lesions can result in severe bone pain or fracture due to the reduced quality of the bone.

There is a multitude of crucial processes during bone metastatic growth. These include tumor growth and tumor–stroma interactions by direct contact and through signaling molecules (reviewed by Lorusso *et al.*<sup>9</sup> and Mundy<sup>10</sup>). The interactions and signaling between the tumor and its direct surroundings result in local pro-angiogenic signaling (reviewed by Voorzanger-Rousselot *et al.*<sup>11</sup> and Guise *et al.*<sup>12</sup>), local activation and infiltration of the innate immune system and local suppression of the adaptive immune system (reviewed by Lin *et al.*<sup>13</sup>). All of these processes have a positive feedback on tumor growth. Moreover, the skeletal metastatic sites are often characterized by a distortion of the delicate balance in bone turnover leading to osteolytic and/or osteoblastic lesions at the metastatic tumor site.

### A Vicious Cycle

The bone matrix holds an abundant store of growth factors, which are released during bone resorption. Many different cell types are involved in the process of bone metastatic growth: tumor cells, endothelial cells and stromal cells, plus the bone specific osteoblasts and osteoclasts and their precursors. Each of these cell types fulfill their own key role in the context of bone metastasis.

Once settled in the bone micro-environment, breast cancer cells are capable of releasing various signaling molecules such as, bone morphogenic proteins (BMPs),



**Figure 1.2: Schematic representation of the vicious cycle of bone metastasis.** Tumor cells stimulate Osteoblasts and stromal cells to express RANKL by producing osteolytic factors as PTHrP, IL-1, IL-6 and IL-11. These factors lead to a downregulation in OPG expression, an inhibitor of RANKL. In turn, RANKL results in increased osteoclastogenesis and osteoclast survival. Mineralized bone matrix is rich in cytokines and growth factors including TGF-β. These factors are released in the bone marrow space upon bone resorption by osteoclasts. In turn, these factors stimulate tumor cell survival, growth, and production of PTHrP and other osteolytic factors which further stimulate osteoclastic resorption. In addition, bone metastases are generally hypoxic leading to an upregulation of HIF-1α and secretion of VEGF, a strong pro-angiogenic factor. CEPs are attracted by leaky tumor vasculature and further stimulates angiogenesis. Tumors recruit Treg cells via a mechanism which is largely unknown. Treg cells inhibit possible immune reactions against the tumor through the downregulation of T & B effector and helper cells.<sup>6,10,14</sup>

insulin-like growth factors (IGFs), transforming growth factor- $\beta$  (TGF- $\beta$ ) and parathyroid hormone-related protein (PTHrP), which in themselves have an effect on bone.<sup>7,15</sup> PTHrP is a signaling molecule involved in mammary gland development and lactation, hence, its strong presence both in the healthy breast as well as in breast cancer. In addition, PTHrP is involved in many other processes as signaling molecule, amongst which the maintenance of a calcium homeostasis.<sup>16–18</sup> These multiple functions of PTHrP are at the core of the pathogenesis of osteolytic bone metastases of breast cancer.

PTHrP, released locally in the bone by metastases, stimulates the expression of receptor activator for nuclear factor- $\kappa$ B ligand (RANKL) on neighboring bone marrow stromal cells and osteoblasts.<sup>10</sup> RANKL signaling stimulates the maturation of osteoclasts from RANK positive precursor cells. Moreover, RANKL prolongs the survival of mature, active, osteoclasts.<sup>19</sup> Osteoclasts resorb the mineralized bone matrix, which in turn causes the release and activation of growth factors and cytokines present in the bone. TGF- $\beta$  is such a factor which is highly present in bone.<sup>20,21</sup>

The released TGF- $\beta$  stimulates tumor cells to produce more osteolytic factors (PTHrP, IL-6, IL-11) that can, in turn, further stimulate osteoclastic resorption and increase the TGF- $\beta$  release from bone.<sup>6,20,22</sup> This feed-forward stimulation of osteoclastic bone resorption is referred to as the “vicious cycle” of bone metastasis (Figure 1.2).<sup>15,22–24</sup> The strong positive feedback between bone destruction and metastatic growth makes these lesions nearly impossible to treat.<sup>10,14</sup> The local bone destruction is the main cause of morbidity in metastatic bone disease.

## Tumor Angiogenesis

Tumors cannot grow without sufficient blood supply making angiogenesis a critical process in tumor growth. In the adult, angiogenesis is a tightly regulated process occurring almost exclusively during wound healing and in ischemic areas. However, at a certain point during tumor growth there is a shift of balance towards angiogenesis. This shift has been called the “angiogenic switch”, a result of crosstalk between the tumor and surrounding healthy tissue.<sup>25</sup>

In the case of bone metastases, angiogenesis is strongly driven by hypoxia. Hypoxia and the stabilization of hypoxia inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) as a key initiators of (tumor-)angiogenesis has been studied extensively and reviewed by Liao and Johnson.<sup>26</sup> VEGF is one of the downstream targets of hypoxia signaling and the main factor involved in pro-angiogenic signaling.<sup>27</sup> Most of the vasculogenic and angiogenic effects of VEGF are mediated through the VEGF receptor 1 (VEGFR1, FLT-1) and VEGF receptor 2 (VEGFR2, Flk-1) expressed on endothelial cells.<sup>28</sup> During angiogenesis, including tumor angiogenesis, both VEGF and VEGFR2 expression are locally upregulated.<sup>29,30</sup>

The one sided pro-angiogenic, mainly VEGF mediated, signaling leads to the formation of an abnormal vascular network. The newly formed vessels are leaky, tortuous and often lack pericytes and a basement membrane.<sup>31,32</sup> Leaky, poorly formed,

vasculature and high levels of VEGF attract circulating endothelial progenitor cells (CEPs). These cells are able to differentiate into endothelial cells and are normally involved in vessel repair, angiogenesis and neo-vascularization, adding up to the already existing pro-angiogenic environment (Figure 1.2).<sup>33,34</sup>

## Molecular Imaging

Molecular imaging is the term used to describe a wide range of imaging tools and techniques that enable the visualization of molecular processes and interactions (functional imaging) or structures and micro-architecture (structural imaging). Molecular imaging modalities can be based on light (e.g. optical imaging), on the use of radioactive tracers (e.g. PET and SPECT), on the use of ultrasound or on differences in magnetic resonance (e.g. MRI). These functional imaging modalities can be combined with structural imaging modalities which provide more anatomical detail such as radiography or computed tomography (CT).

When performing research on bone metastases, it is important to follow both structural and functional developments in and around the tumor. Structural imaging modalities are used to follow diseased induced changes to the skeleton whereas functional imaging is to follow processes such as matrix degeneration, tumor angiogenesis and tumor growth. The non-invasive character of optical imaging, imaging modalities based on detection of light, makes it possible to follow animals over time throughout the experimental period.

### Whole Body Optical Imaging

Optical imaging of cancer presents a challenge because tumor cells usually do not have a specific optical quality that clearly distinguishes them from normal tissue. However, the field of whole body optical imaging has been transformed over the last decades by improvements in camera detection systems as well as better tools for making clonal cell lines or transgenic animal models with light-generating capabilities or specific fluorescent properties.

The term optical imaging includes all of the imaging techniques based on the detection of photons with wavelengths in the ultraviolet, visible, near-infrared and infrared parts of the spectrum. These photons are emitted from living cells, tissues or animals through either bioluminescence or fluorescence. As a result, optical imaging can be divided in: bioluminescence imaging (BLI) and fluorescence imaging (FLI). Despite the similarities in their applications, BLI and FLI both have their own characteristics, strengths and weaknesses such as differences in availability, sensitivity, signal to noise ratio (SNR) and interference by background emission from tissues.<sup>35–38</sup>

The choice of tools, such as whether to use FLI or BLI, is determined by the questions needing to be addressed, e.g. FLI allows total cells *in vivo* to be measured as well as *in vitro* and *ex vivo* analysis to be performed whereas BLI often gives an



indication of metabolizing cell activity. Therefore, BLI has evolved into a standard modality in pre-clinical research to follow tumor growth non-invasively over time.

### **X-rays and $\mu$ CT**

X-rays dominated the field of skeletal imaging ever since Rontgen's publication of a photo of his wife's hand and various other shadow images in Science back in 1896.<sup>39-41</sup> The subsequent work of people like Alessandro Vallebona and William Watson formed the basis of X-ray tomography. It is during the 1970s that X-ray-based imaging underwent revolutionary changes after advances in digital computing enabled the development of CT by Godfrey Hounsfield.<sup>42,43</sup>

Radiographs of small animals are made in the same way as their human counterpart. The technique is not much different from the method described by Röntgen. The subject is placed between a concealed photographic film or digital X-ray camera and an X-ray point source. The recorded image is a two dimensional (2D) shadow projection of the subject.

Relatively new are specialized small animal  $\mu$ CT scanners. These machines can produce high resolution three dimensional (3D) datasets of *in vivo* and *ex vivo* specimens. In general, 3D methodologies are preferable over their 2D counterparts as they give a better approximation of the real life situation. Moreover,  $\mu$ CT can potentially be used to quantify osteoblastic lesions as well as osteolytic lesions, something that is not possible with radiography. However, data analysis of 3D datasets can be tedious and only few standardized protocols for data analysis are in place since the imaging techniques are relatively new.<sup>44-47</sup>

## Contribution and Outline of this Thesis

The aim of this work was to develop methods to measure structural changes in the skeleton using  $\mu$ CT. In addition, these new methods should be able to quantify biologically relevant changes. In order to do this, normalized methods to analyze  $\mu$ CT scans and perform quantitative measurements within these datasets are described in this thesis. These techniques were combined with a biological angiogenesis assay and used as research tools in a study comparing various different combination treatments of bone metastases.

Chapter 2 describes a manual  $\mu$ CT based method to assess specific changes in bone volume. The method allows the user to select normalized volumes of interest based on manual input. In addition, the user can generate normalized cross sections and longitudinal sections for side-by-side presentations, comparison of cortical thickness and validation of histological findings.

Chapter 3 describes an automated  $\mu$ CT based method to assess disease induced changes in bone volume and thickness. The segmentation and volume measurements are fully automated in order to minimize observer bias. The segmentation algorithm is able to find the region of interest in whole-body rodent  $\mu$ CT scans, regardless of the animal posture during the scan. The exact location of volumetric changes can be assessed using automatically generated color coded cortical thickness maps.

Chapter 4 gives an overview of the advances made by the LUMC departments of Endocrinology and Radiology - Image Processing (LKEB) in multi-modality molecular imaging with an emphasis on  $\mu$ CT. This puts Chapters 2 and 3 in a broader perspective by linking  $\mu$ CT to other imaging modalities.

Chapter 5 describes an angiogenesis assay. The assay enables the differentiation between anti-angiogenic and vascular disrupting properties of compounds. In addition, the assay will indicate the main mechanism underlying the anti-angiogenic properties.

Chapter 6 discusses the efficacy of the suggested combination treatment consisting of ENMD-1198, "metronomic" cyclophosphamide and bisphosphonates. In addition, this chapter is exemplary on how the described angiogenesis assay,  $\mu$ CT quantification techniques, radiographs and optical imaging can be combined in a set of experiments to answer biological questions and assess treatment efficacy.

## References

1. Surveillance, epidemiology, and end results (seer) program. <http://www.seer.cancer.gov/> - Total U.S., 1969-2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2011 Apr.
2. DeSantis C, Jemal A, Ward E, and Thun MJ. Temporal trends in breast cancer mortality by state and race. *Cancer Causes Control*, 2008 Jun;19(5):537-45.
3. Abrams HL, Spiro R, and Goldstein N. Metastases in carcinoma; analysis of 1000 autopsied cases. *Cancer*, 1950 Jan;3(1):74-85.
4. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res*, 2006 Oct;12(20 Pt 2):6243s-6249s.
5. Paget S. The distribution of secondary growths in cancer of the breast. *Lancet*, 1889; 1:571-3.
6. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, and Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. *Clin Cancer Res*, 2006 Oct;12(20 Pt 2):6213s-6216s.
7. Reddi AH, Roodman D, Freeman C, and Mohla S. Mechanisms of tumor metastasis to the bone: challenges and opportunities. *J Bone Miner Res*, 2003 Feb;18(2):190-4.
8. Roodman GD. Mechanisms of bone metastasis. *N Engl J Med*, 2004 Apr;350(16):1655-64.
9. Lorusso G and Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. *Histochem Cell Biol*, 2008 Dec;130(6):1091-103.
10. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. *Nat Rev Cancer*, 2002 Aug;2(8):584-93.
11. Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, and Garnerio P. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a cross-sectional and longitudinal evaluation. *Br J Cancer*, 2006 Aug;95(4):506-14.
12. Guise TA and Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. *Clin Orthop Relat Res*, 2003 Oct;415(Suppl):S32-8.
13. Lin WW and Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. *J Clin Invest*, 2007 May;117(5):1175-83.
14. Guise TA and Mundy GR. Cancer and bone. *Endocr Rev*, 1998 Feb;19(1):18-54.
15. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Córdón-Cardo C, Guise TA, and Massagué J. A multigenic program mediating breast cancer metastasis to bone. *Cancer Cell*, 2003 Jun;3(6):537-49.

16. Allgrove J. Physiology of calcium, phosphate and magnesium. *Endocr Dev*, 2009; 16:8–31.
17. Datta NS and Abou-Samra AB. Pth and pthrp signaling in osteoblasts. *Cell Signal*, 2009 Aug;21(8):1245–54.
18. Mamillapalli R, VanHouten J, Zawalich W, and Wysolmerski J. Switching of g-protein usage by the calcium-sensing receptor reverses its effect on parathyroid hormone-related protein secretion in normal versus malignant breast cells. *J Biol Chem*, 2008 Sep; 283(36):24435–47.
19. Boyce BF and Xing L. Functions of rank/rank/opg in bone modeling and remodeling. *Arch Biochem Biophys*, 2008 May;473(2):139–46.
20. Kiriya T, Gillespie MT, Glatz JA, Fukumoto S, Moseley JM, and Martin TJ. Transforming growth factor beta stimulation of parathyroid hormone-related protein (pthrp): a paracrine regulator? *Mol Cell Endocrinol*, 1993 Mar;92(1):55–62.
21. Pivonka P, Zimak J, Smith DW, Gardiner BS, Dunstan CR, Sims NA, Martin TJ, and Mundy GR. Model structure and control of bone remodeling: a theoretical study. *Bone*, 2008 Aug;43(2):249–63.
22. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, and Guise TA. Tgf-beta signaling blockade inhibits pthrp secretion by breast cancer cells and bone metastases development. *J Clin Invest*, 1999 Jan;103(2):197–206.
23. Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, and ten Dijke P. The tumor suppressor smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. *Cancer Res*, 2006 Feb;66(4):2202–9.
24. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, and Massagué J. Breast cancer bone metastasis mediated by the smad tumor suppressor pathway. *Proc Natl Acad Sci U S A*, 2005 Sep;102(39):13909–14.
25. Hanahan D and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell*, 1996 Aug;86(3):353–64.
26. Liao D and Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. *Cancer Metastasis Rev*, 2007 Jun;26(2):281–90.
27. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, and Goldberg MA. Negative regulation of hypoxia-inducible genes by the von hippel-lindau protein. *Proc Natl Acad Sci U S A*, 1996 Oct;93(20):10595–9.
28. Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, M°ller NP, Risau W, and Ullrich A. High affinity vegf binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. *Cell*, 1993 Mar;72(6):835–46.

29. Rissanen TT, Vajanto I, Hiltunen MO, Rutanen J, Kettunen MI, Niemi M, Leppänen P, Turunen MP, Markkanen JE, Arve K, Alhava E, Kauppinen RA, and Ylä-Herttuala S. Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (kdr/flk-1) in ischemic skeletal muscle and its regeneration. *Am J Pathol*, 2002 Apr;160(4):1393–403.
30. Vajkoczy P, Farhadi M, Gaumann A, Heidenreich R, Erber R, Wunder A, Tonn JC, Menger MD, and Breier G. Microtumor growth initiates angiogenic sprouting with simultaneous expression of vegf, vegf receptor-2, and angiopoietin-2. *J Clin Invest*, 2002 Mar;109(6):777–85.
31. Carmeliet P and Jain RK. Angiogenesis in cancer and other diseases. *Nature*, 2000 Sep;407(6801):249–57.
32. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, and Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. *Cancer Res*, 2000 Mar;60(5):1388–93.
33. Rabelink TJ, de Boer HC, de Koning EJP, and van Zonneveld AJ. Endothelial progenitor cells: more than an inflammatory response? *Arterioscler Thromb Vasc Biol*, 2004 May;24(5):834–8.
34. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, and Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res*, 1999 Aug;85(3):221–8.
35. Snoeks TJA, Löwik CWGM, and Kaijzel EL. 'in vivo' optical approaches to angiogenesis imaging. *Angiogenesis*, 2010 Jun;13(2):135–47.
36. Snoeks TJA, Khmelinskii A, Lelieveldt BPF, Kaijzel EL, and Löwik CWGM. Optical advances in skeletal imaging applied to bone metastases. *Bone*, 2011 Jan;48(1):106–14.
37. Taroni P, Pifferi A, Torricelli A, Comelli D, and Cubeddu R. In vivo absorption and scattering spectroscopy of biological tissues. *Photochem Photobiol Sci*, 2003 Feb;2(2):124–9.
38. Weissleder R and Ntziachristos V. Shedding light onto live molecular targets. *Nat Med*, 2003 Jan;9(1):123–8.
39. Goodspeed AW. Experiments on the rontgen x-rays. *Science*, 1896 Feb;3(59):236–7.
40. Pupin MI. Rontgen rays. *Science*, 1896 Feb;3(59):231–5.
41. Röntgen WC. On a new kind of rays. *Science*, 1896 Feb;3(59):227–31.
42. Ambrose J and Hounsfield G. Computerized transverse axial tomography. *Br J Radiol*, 1973 Feb;46(542):148–9.
43. Hounsfield GN. Computerized transverse axial scanning (tomography). 1. description of system. *Br J Radiol*, 1973 Dec;46(552):1016–22.

44. Bussard KM and Mastro AM. Ex-vivo analysis of the bone microenvironment in bone metastatic breast cancer. *J Mammary Gland Biol Neoplasia*, 2009 Dec;14(4):387–95.
45. Johnson LC, Johnson RW, Munoz SA, Mundy GR, Peterson TE, and Sterling JA. Longitudinal live animal micro-ct allows for quantitative analysis of tumor-induced bone destruction. *Bone*, 2011 Jan;48(1):141–51.
46. Kaijzel EL, Snoeks TJA, Buijs JT, van der Pluijm G, and Löwik CWGM. Multimodal imaging and treatment of bone metastasis. *Clin Exp Metastasis*, 2009;26(4):371–9.
47. Kok P, Baiker M, Hendriks EA, Post FH, Dijkstra J, Löwik CWGM, Lelieveldt BPF, and Botha CP. Articulated planar reformation for change visualization in small animal imaging. *IEEE Trans Vis Comput Graph*, 2010;16(6):1396–404.



